Published in J Affect Disord on June 10, 2013
Compulsive features in behavioural addictions: the case of pathological gambling. Addiction (2011) 3.28
Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: Bipolar disorder. Am J Hum Genet (2003) 3.02
The diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int (2013) 2.73
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry (2008) 2.64
An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry (2014) 2.43
Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry (2010) 2.41
Does mindfulness training improve cognitive abilities? A systematic review of neuropsychological findings. Clin Psychol Rev (2010) 2.17
Broadening our horizon: response to commentaries. Addiction (2012) 2.11
Reduced resting-state functional connectivity between amygdala and orbitofrontal cortex in social anxiety disorder. Neuroimage (2011) 2.05
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol (2009) 1.89
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry (2009) 1.87
Circadian clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. Neuropsychopharmacology (2002) 1.82
Three circadian clock genes Per2, Arntl, and Npas2 contribute to winter depression. Ann Med (2007) 1.77
Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry (2006) 1.77
Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry (2005) 1.67
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry (2003) 1.66
Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol (2007) 1.64
Evaluation of the Two-Way Communication Checklist as a clinical intervention. Results of a multinational, randomised controlled trial. Br J Psychiatry (2004) 1.61
Serum response factor controls neuronal circuit assembly in the hippocampus. Nat Neurosci (2006) 1.61
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry (2010) 1.61
Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry (2007) 1.60
Anger attacks in depression--evidence for a male depressive syndrome. Psychother Psychosom (2005) 1.55
The serotonin-1A receptor distribution in healthy men and women measured by PET and [carbonyl-11C]WAY-100635. Eur J Nucl Med Mol Imaging (2008) 1.55
International Consensus Group on Bipolar I Depression Treatment Guidelines. J Clin Psychiatry (2004) 1.50
The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder. Eur Arch Psychiatry Clin Neurosci (2012) 1.49
Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract (2012) 1.49
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry (2013) 1.48
Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry (2006) 1.46
Consensus document on European brain research. Eur J Neurosci (2011) 1.45
A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry (2004) 1.44
The serotonin-1A receptor in anxiety disorders. Biol Psychiatry (2009) 1.40
Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol (2002) 1.39
Essential role of MCM proteins in premeiotic DNA replication. Mol Biol Cell (2002) 1.38
Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol (2008) 1.36
Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J (2009) 1.35
Noradrenaline in mood and anxiety disorders: basic and clinical studies. Int Clin Psychopharmacol (2003) 1.34
Accumulation of foam cells in liver X receptor-deficient mice. Circulation (2002) 1.34
Blunted HPA axis response to stress influences susceptibility to posttraumatic stress response in rats. Biol Psychiatry (2006) 1.32
Serotonin transporter gene variants and behavior: a comprehensive review. Curr Drug Targets (2006) 1.29
Pharmacogenetics of antidepressant response. J Psychiatry Neurosci (2011) 1.28
Personality and attempted suicide. Analysis of anger, aggression and impulsivity. J Psychiatr Res (2009) 1.26
Pontocerebellar hypoplasia type 6 caused by mutations in RARS2: definition of the clinical spectrum and molecular findings in five patients. J Inherit Metab Dis (2012) 1.26
Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry (2009) 1.25
Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol (2009) 1.25
Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. Arch Gen Psychiatry (2002) 1.24
Genome scan for susceptibility loci for schizophrenia and bipolar disorder. Biol Psychiatry (2002) 1.23
Differential modulation of the default mode network via serotonin-1A receptors. Proc Natl Acad Sci U S A (2012) 1.22
Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol (2006) 1.21
The neuropeptide Y (NPY)-ergic system is associated with behavioral resilience to stress exposure in an animal model of post-traumatic stress disorder. Neuropsychopharmacology (2011) 1.21
An animal model of posttraumatic stress disorder: the use of cut-off behavioral criteria. Ann N Y Acad Sci (2004) 1.20
Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry (2002) 1.19
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol (2009) 1.19
Setting apart the affected: the use of behavioral criteria in animal models of post traumatic stress disorder. Neuropsychopharmacology (2004) 1.19
Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med (2012) 1.19
Severe intestinal obstruction on induced smooth muscle-specific ablation of the transcription factor SRF in adult mice. Gastroenterology (2007) 1.19
Fully exploratory network independent component analysis of the 1000 functional connectomes database. Front Hum Neurosci (2012) 1.18
Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H-MRS at 3 Tesla. Invest Radiol (2003) 1.17
Induction of the lac promoter in the absence of DNA loops and the stoichiometry of induction. Nucleic Acids Res (2006) 1.16
The relevance of differential response to trauma in an animal model of posttraumatic stress disorder. Biol Psychiatry (2003) 1.15
Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry (2009) 1.13
Glucocorticoid receptor gene-based SNP analysis in patients with recurrent major depression. Neuropsychopharmacology (2006) 1.12
Adverse reactions to antidepressants. Br J Psychiatry (2009) 1.12
Interaction between serotonin transporter gene, catechol-O-methyltransferase gene and stressful life events in mood disorders. Int J Neuropsychopharmacol (2006) 1.10
Cape Town consensus on posttraumatic stress disorder. CNS Spectr (2009) 1.09
Early post-stressor intervention with high-dose corticosterone attenuates posttraumatic stress response in an animal model of posttraumatic stress disorder. Biol Psychiatry (2008) 1.08
Regional sex differences in grey matter volume are associated with sex hormones in the young adult human brain. Neuroimage (2009) 1.08
Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol (2007) 1.07
Serum response factor contributes selectively to lymphocyte development. J Biol Chem (2007) 1.07
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. World J Biol Psychiatry (2011) 1.06
Bright-light therapy in the treatment of mood disorders. Neuropsychobiology (2011) 1.05
Long-term down-regulation of BDNF mRNA in rat hippocampal CA1 subregion correlates with PTSD-like behavioural stress response. Int J Neuropsychopharmacol (2007) 1.05
The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry (2004) 1.04
Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology (2009) 1.04
Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. Neuroimage (2009) 1.04
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry (2002) 1.04
Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol (2007) 1.04
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psychiatry (2011) 1.03
Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. J Affect Disord (2011) 1.03
Loss of serum response factor in keratinocytes results in hyperproliferative skin disease in mice. J Clin Invest (2009) 1.03
Refractory obsessive-compulsive disorder: state-of-the-art treatment. J Clin Psychiatry (2002) 1.03
Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci (2003) 1.03